Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › bone metastases

Bone metastases

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for bone metastases

20 trials tracked for bone metastases: 8 in phase 3 or 4 and 4 with published results. The most-cited published study has 447 citations.

20Trials tracked
8Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 8 Phase 2 6 Phase 1 1 Other / NA 5
  1. Phase 3 Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma Completed · 447 cited
  2. Phase 3 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms Completed · 228 cited
  3. Phase 3 Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed · 173 cited
  4. Phase 3 QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas Completed · 166 cited
  5. Phase 3 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer Completed
  6. Phase 3 A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases Completed
Show 14 more trials
  1. Phase 3 Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma. Completed
  2. Phase 3 A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. Completed
  3. Phase 2 Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer Completed
  4. Phase 2 Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis Completed
  5. Phase 2 A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) Completed
  6. Phase 2 Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Completed
  7. Phase 2 Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases Completed
  8. Phase 2 Open Label Extension In Cancer Patients Completed
  9. Phase 1 A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer Completed
  10. N/A ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain Completed
  11. N/A EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy Completed
  12. N/A Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology Completed
  13. N/A Rapid Radiation Therapy for Painful Osseous Metastatic Disease Completed
  14. N/A A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Bone metastases: what the trials found

Several trials evaluated the efficacy of Denosumab in managing skeletal-related events (SREs). Studies demonstrated significant improvements in time to first SRE, with results showing statistically significant non-inferiority and superiority across different trial cohorts [1, 6, 8].

Zoledronic acid was shown to significantly improve the time to the first SRE, demonstrating both non-inferiority and superiority in clinical outcomes 7.

Radium-223 dichloride (Xofigo) demonstrated significant improvements in overall survival, time to total alkaline phosphatase (ALP) progression, and percentage of patients with a total ALP response at week 12 5. Safety data for Radium-223 also established the frequency of high-grade treatment-emergent adverse events 13.

Hypofractionated radiation treatment was associated with significant improvements in pain response among evaluable participants 2.

Recent results — preliminary, needs further review

  • A study on CT-guided bone percutaneous procedures is currently under investigation and not yet corroborated 16.

For the clinician treating this condition

  • Denosumab and Zoledronic acid are established interventions for reducing the time to first skeletal-related events (SREs) in patients with bone metastases.
  • Radium-223 dichloride is an established treatment associated with improved overall survival and progression-free metrics in specific patient populations [5, 13].
  • Hypofractionated radiation therapy has been shown to improve pain response in patients with bone involvement 2.

AI synthesis of 5 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Prophylactic dexamethasone reduces risk of radiation induced pain flares in patients with bone metastases
Palliative Care Meta-analysis
Prophylactic dexamethasone reduces risk of radiation induced pain flares in patients with bone metastases Dexamethasone reduces radiation induced pain for bone metastasis patients
This meta-analysis evaluated the use of prophylactic dexamethasone in patients with bone metastases undergoing palliative radiotherapy. The …
A steroid treatment may help prevent sudden spikes in pain for patients receiving radiation therapy for cancer that has spread to the bone.
Frontiers Aug 23, 2026
Palliative care consultation for bone metastases radiotherapy patients shows no outcome data in protocol
Oncology RCT
Palliative care consultation for bone metastases radiotherapy patients shows no outcome data in protocol Hospital palliative care teams may improve satisfaction for advanced cancer patients
This is a study protocol for a randomized controlled trial in patients with bone metastases referred for radiotherapy. The intervention is c…
A hospital trial suggests that adding palliative care consultations could boost satisfaction for patients with bone metastases and advanced …
May 23, 2026
CT-Based Radiomics Model Predicts Pain Relief After Radiotherapy for Bone Metastases
Oncology Guideline
CT-Based Radiomics Model Predicts Pain Relief After Radiotherapy for Bone Metastases AI Predicts Who Will Get Pain Relief from Radiation
This retrospective dual-center study developed a CT-based radiomics model (KNN) to predict pain relief after palliative radiotherapy in 134 …
You’re sitting in the oncology clinic, tired from weeks of pain.
Frontiers Apr 24, 2026
225Ac-DOTA-IBA shows pain relief and imaging responses in bone metastases preliminary study
Oncology
225Ac-DOTA-IBA shows pain relief and imaging responses in bone metastases preliminary study Small preliminary study shows promising pain relief with new bone cancer treatments
A preliminary study of 14 patients with bone metastases found that 225Ac-DOTA-IBA at 3.7 MBq per cycle led to pain relief in 92.9% after the…
New bone cancer drugs relieved pain in 93% of patients and improved daily function with no severe side effects in this early study.
Apr 14, 2026

Questions about bone metastases

Will seeing a palliative care team help my bone metastases pain?

Seeing a palliative care team can help manage bone metastases pain by improving satisfaction with care and reducing symptom burden through a multidisciplinary approach.

Full answer →